1 |
Bennett CL, Nebeker JR, Yarnold PR, et al., Evaluation of serious adverse drug reaction. Arch Intern Med 2007; 167: 1041-49.
DOI
|
2 |
Moore TJ, Cohen MR, Furberg CD. Serious adverse events reported to the Food and Drug Administration, 1995-2005. Arch Intern Med 2007; 167: 1752-59.
DOI
|
3 |
Website. Available at http://www.nso.go.kr.
|
4 |
DICKSON, M. & JACOBZONE, S. Pharmaceutical use and expenditure for cardiovascular disease and stroke: A study of 12 OECD countries. Paris, Organisation for Economic Co-operation and Development. 2003.
|
5 |
KUIJPERS, M. A. J., VAN MARUM, R. J., et al., Relationship between polypharmacy and underprescribing. British Journal of Clinical Pharmacology 2007; 65: 130-3.
|
6 |
WIEDENMAYER, K. Rational use of medicines. IN ANDERSON, S., HUSS, R., SUMMERS, R. & WIEDENMAYER, K.(Eds.) Managing pharmaceuticals in international health. Basel, Birkhauser 2004; 141-52.
|
7 |
WINDMEIJER, F., DE LAAT, E., DOUVEN, R, et al., Pharmaceutical promotion and GP prescription behaviour. Heath Economics 2006; 15: 5-18.
DOI
|
8 |
Roughead E, Pratt N, Peck R, et al., Improving medication safety: influence of a patient-specific prescriber feedback program on rate of medication reviews performed by Australian general medical practitioners. Pharmacoepidemiol Drug Saf 2007; 16: 797-803.
DOI
|
9 |
Korea Food and Drug Administration[internet]. Announcement of drug safety information surveillance. [cited 2008 Jun 30] Available from: http://kfda.go.kr [accessed 2012 Nov 27]
|
10 |
Kim HK, Kim YS, Pak YG. A Survey on introduction of pharmacovigilance specialist certification system. Journal of pharmacoepidemiology and risk management 2010; 3: 36-45.
|
11 |
Figuerias A, Herdeiro MT, Polonia J, et al., An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. JAMA 2006; 296: 1086-93.
DOI
|
12 |
Kelly M, Kaye KI, Davis SR, et al., Factors influencing adverse drug reaction reporting in New South Wlaes teaching hospitals. Drug Saf 2004; 22: 161-8.
|
13 |
World Health Organization: Safety of Medicines: A guide to detecting and reporting adverse drug reactions. WHO, EDM, QSM, 2002.
|
14 |
Davies EC, Green CF, Taylor S, et al., Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One. 2009; 4: e4439.
DOI
|
15 |
Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash) 2001; 41(2): 192-9.
|
16 |
Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, EQUUS: Safety Monitoring of Medicinal Products Guidelines for setting up and running a Pharmacovigilance Centre. London, 2000.
|
17 |
Nissen SE, K W. Rosiglitazone Revisited: An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality. Arch Intern Med 2010; 170: 1191-201.
|
18 |
Rhew KY, Lee S. Analysis of the Korea Food and Drug Administration Adverse Drug Reaction Reports. Kor J Clin Pharm 2011; 21(2): 138-44.
|
19 |
Choi YH, Sohn UD. The Surveillance of Adverse Drug Reaction (ADR) Reported. Kor J Clin Pharm 2003; 13(2): 72-81.
|
20 |
Lim HR, Park EH. Analysis of ADR Reporting Types in Yonsei University Healthcare System. J. Kor. Soc. Health- Syst. Pharm 2011; 28(2): 127-35.
|
21 |
Rhew KY, Cho HK, Lee S. Characteristics of Cardiovascular Adverse Drug Reactions Reported to KFDA. Kor J Clin Pharm 2012; 22(1): 41-6.
|